J&J $34 Million Talc Verdict: Alameda Jury Splits Fault 40/60 With Dr. Scholl's in Reikes Mesothelioma Case

The J&J $34 million talc verdict came on Monday, November 9, 2026, when a jury in Alameda County Superior Court in Oakland awarded $34.21 million to Kevin Reikes, a man with mesothelioma, and his wife Tina, after finding that Johnson's Baby Powder was defective and that Johnson & Johnson's failure to warn was a substantial factor in causing his cancer. The headline number overstates J&J's likely bill, because the same jury assigned only 40% of fault to J&J and 60% to Dr. Scholl's foot powder, whose maker settled before trial, and California's Proposition 51 limits each defendant's share of non-economic damages to its percentage of fault.

The case, Reikes et al. v. Block Drug Company et al., No. 25CV157993, is the second plaintiff's verdict against J&J in a talc mesothelioma trial in four days, after a Massachusetts jury awarded about $1.9 million in the Haddad case on November 6. It is also a reminder that mesothelioma claims sit entirely outside the company's proposed $5.5 billion ovarian cancer resolution and continue to be tried one at a time in state courts. This piece sets out what has been reported about the trial and what has not, explains how the 40/60 allocation works under California law, models J&J's exposure under several damages splits, places Reikes against J&J's California talc record, walks through the post-trial and appeal timetable, and closes with what the verdict means for plaintiffs' firms, defendants, insurers and funders.

How much did the California jury award against J&J in the Reikes talc case?

The jury awarded $34.21 million. That precise figure comes from a release issued on behalf of the plaintiffs' trial firm, Dallas-based Iola, Gross & Forbes-King. Law.com's The Recorder, reporting the verdict the same day, described it as an award of more than $34 million to Kevin and Tina Reikes, and reported that jurors found J&J 40% liable for the plaintiffs' medical costs and pain and suffering.

Two points about the number need emphasis. First, the public reporting describes $34.21 million as the jury's award, and the fault allocation as a separate finding. Neither report has published the verdict form or a proposed judgment, so it is not yet public whether $34.21 million is the gross damages total before allocation (the usual reading of a plaintiff-side headline, and the one this analysis adopts) or a figure already reduced to J&J's share. Second, the reporting refers to "medical costs and pain and suffering," which signals that the award includes both economic damages (past and future medical expenses) and non-economic damages (pain, suffering and, for Tina Reikes, loss of consortium). The split between those categories determines how much J&J owes, for reasons explained below.

No punitive damages were awarded, Law.com reported. The entire award is compensatory.

Who is Kevin Reikes and what was Reikes v. Block Drug about?

Kevin Reikes is a Northern California man who, according to the plaintiffs' release, was diagnosed with mesothelioma in June 2025 after years of using talc-based products, including Johnson's Baby Powder. He and his wife, Tina Reikes, sued a group of talc product companies in Alameda County Superior Court. The case caption, Kevin M. Reikes et al. v. Block Drug Company et al., takes its name from the first-listed defendant rather than from J&J, which is common in California asbestos litigation where complaints name many manufacturers, distributors and retailers and the list narrows as defendants settle or are dismissed.

By the time the case reached the jury, J&J was the only defendant left at trial, Law.com reported. The plaintiffs' release states that Dr. Scholl's settled before trial. The case number's "25CV" prefix indicates a 2025 filing, consistent with a diagnosis in June 2025 and a fast track to trial, which is typical of mesothelioma cases in California, where plaintiffs with a terminal diagnosis can seek trial preference.

The core theory was the one that has driven talc mesothelioma litigation for a decade: that the talc J&J sourced for its baby powder was contaminated with asbestos, that Reikes inhaled the asbestos-containing dust during routine use, and that J&J knew or should have known of the risk and failed to warn consumers. The jury accepted that theory on the two questions the release highlights. It found Johnson's Baby Powder was defective, and it found that J&J's failure to warn was a substantial factor in causing Reikes' mesothelioma.

The trial ran about eight weeks, according to the release, which names Sam Iola and Shawna Forbes-King as the lawyers who presented the plaintiffs' evidence. Law.com's coverage identifies Kirkland & Ellis and King & Spalding as J&J's counsel in the talc trials it reviewed that week.

Several details have not been published and are not stated here: the presiding judge, the precise verdict-form questions, the line-item damages split, the jury's vote, the amount of the Dr. Scholl's settlement, and the identity of the entity that made or sold the Dr. Scholl's product during the years Reikes used it.

Why did the jury assign 60% of fault to Dr. Scholl's?

Because California allows a jury to apportion fault to settled defendants and non-parties whose products contributed to the injury, and the evidence at trial evidently persuaded these jurors that Reikes' exposure to a second talc product, Dr. Scholl's foot powder, was the larger contributor. The allocation question is distinct from liability: the jury found J&J liable, and then decided what share of the total fault J&J bears.

The mechanism is Proposition 51, the Fair Responsibility Act of 1986, codified at Civil Code section 1431.2. In an action for personal injury based on principles of comparative fault, it makes each defendant's liability for non-economic damages "several only," in proportion to that defendant's percentage of fault. To apply it, the jury assigns percentages to every person or entity whose fault contributed to the harm, including defendants who settled before trial, and the verdict form reflects those percentages even though only one defendant was present in the courtroom.

For a period it was argued that Proposition 51 could not apply in strict products liability cases, because strict liability does not depend on fault in the ordinary sense. California courts rejected that position for cases like this one. In Arena v. Owens-Corning Fiberglas Corp. (1998), an asbestos case arising from shipyard exposure, the Court of Appeal held that Proposition 51 applies in strict products liability actions where multiple products contributed to the plaintiff's injury and the evidence gives a basis for allocating fault among them. The rule is different where the defendants are in the same chain of distribution for a single product, but separate manufacturers of separate products, which is what J&J and the Dr. Scholl's maker are, fall within Arena.

For J&J, a 60% allocation to another product is a significant trial result even in a losing case. The defense in many talc mesothelioma trials has pointed to alternative exposures, such as other cosmetic talcs, automotive brake parts, occupational asbestos or naturally occurring sources, to argue that J&J's product was not a cause at all. In Reikes, that argument did not defeat liability, but it moved most of the fault to another manufacturer. By contrast, the Los Angeles jury in the June 2026 Lozano trial assigned 100% of responsibility to J&J and found that no non-party, including other cosmetic companies and automotive part makers, was at fault.

J&J $34 million talc verdict: how much will J&J actually pay?

Less than $34.21 million, and likely substantially less, but the exact figure depends on the verdict's economic/non-economic split and the Dr. Scholl's settlement amount, neither of which has been published. Under section 1431.2, J&J owes only 40% of the non-economic damages. Economic damages remain joint and several, so J&J is liable for the full economic award, reduced by any credit for the portion of the Dr. Scholl's settlement attributable to economic damages under Code of Civil Procedure section 877. There is no settlement offset against the non-economic share, because a settling defendant's payment toward non-economic damages is treated as discharging that defendant's own several share, not the non-settling defendant's.

The table models J&J's maximum share under three illustrative splits of the $34.21 million award, before any settlement credit. These are scenarios, not reported figures.

Scenario (share of award that is economic)	Economic damages (joint and several)	Non-economic damages	J&J's 40% of non-economic	J&J maximum before settlement credit
0% economic	$0	$34.21 million	$13.684 million	$13.684 million
10% economic	$3.421 million	$30.789 million	$12.316 million	$15.737 million
25% economic	$8.553 million	$25.658 million	$10.263 million	$18.816 million

Two conclusions follow. First, in every plausible scenario, J&J's exposure on the verdict as returned is somewhere between about 40% and 55% of the headline figure, because mesothelioma awards are dominated by pain and suffering and loss of consortium rather than medical bills. Second, the settlement credit can push the economic component close to zero if the Dr. Scholl's settlement was large relative to the medical-expense award, since the credit is applied against the economic damages for which J&J is jointly liable.

Interest then runs on whatever judgment is entered. California post-judgment interest accrues at 10% per year on civil money judgments. If the judgment against J&J were around $14 million, interest would add about $1.4 million for each year an appeal remains pending. If the plaintiffs served a statutory offer to compromise under Code of Civil Procedure section 998 and the judgment beats it, Civil Code section 3291 also allows prejudgment interest at 10% from the date of the offer in a personal injury case, which can add materially to a judgment in a case filed in 2025 and tried in late 2026. Whether a section 998 offer was made has not been reported.

Were punitive damages awarded in the Reikes talc verdict?

No. Law.com reported that the verdict did not include punitive damages. Public reports do not state whether the jury considered and declined a punitive claim or whether the court removed punitive damages from the case before deliberations.

In California, punitive damages under Civil Code section 3294 require clear and convincing evidence of malice, oppression or fraud, and for a corporate defendant, proof that the conduct was authorized or ratified by an officer, director or managing agent. That standard has become a significant obstacle for talc plaintiffs. In the Lozano case in Los Angeles, the trial judge granted J&J a directed verdict on punitive damages before the jury reached them. In the Mae Moore case, a Los Angeles jury in October 2025 awarded $16 million in compensatory damages and $950 million in punitive damages, but Los Angeles Superior Court Judge Ruth Ann Kwan struck the punitive award on March 13, 2026, finding the plaintiffs had not met the clear and convincing evidence standard for malice, while leaving the compensatory award intact.

The absence of punitive damages narrows the post-trial fight. J&J's challenge to Reikes will focus on liability, causation and the size of the compensatory award, not on constitutional ratio arguments of the kind that dominate appeals from nine- and ten-figure punitive verdicts.

Will Johnson & Johnson appeal the California talc verdict?

J&J's public response to the J&J $34 million talc verdict had not appeared in the reporting reviewed for this article, but the company has said it will appeal every recent adverse talc mesothelioma verdict. After the June 2026 Lozano verdict, J&J's litigation chief Erik Haas said the company would "immediately appeal." After the November 6 Haddad verdict in Massachusetts, J&J's head of litigation, Aviva Wein, said the same. J&J maintains that its talc did not contain asbestos and does not cause cancer, and an appeal in Reikes would be consistent with that position.

The California timetable runs as follows.

Step	Rule	Deadline or effect
Entry of judgment	Code Civ. Proc. § 664	Court enters judgment on the verdict, applying the fault allocation and any settlement credit
Notice of intent to move for new trial	Code Civ. Proc. § 659	Within 15 days of notice of entry of judgment (or 180 days after entry if no notice)
Motion for judgment notwithstanding the verdict	Code Civ. Proc. § 629	Same timing as new-trial motion
Court's power to rule on new trial	Code Civ. Proc. § 660	Expires 75 days after notice of entry of judgment; motion denied by operation of law if not decided
Notice of appeal	Cal. Rules of Court, rule 8.104	60 days after notice of entry of judgment, extended under rule 8.108 by timely post-trial motions
Stay of enforcement pending appeal	Code Civ. Proc. § 917.1	Undertaking of 1.5 times the judgment if given by an admitted surety insurer
Post-judgment interest	Code Civ. Proc. § 685.010	10% per year from entry of judgment

An appeal from Alameda County goes to the First District Court of Appeal in San Francisco. Expect J&J to raise evidentiary and expert rulings, the sufficiency of the evidence that the specific baby powder Reikes used contained asbestos, and the size of the non-economic award. The plaintiffs, for their part, may challenge the 60% allocation to Dr. Scholl's if they contend the evidence did not support it, since every percentage point moved back to J&J increases its several share of the non-economic damages.

How does the Reikes verdict compare with other J&J talc verdicts in California?

It is one of the larger compensatory-only talc mesothelioma awards in California, and the only one among the California verdicts below in which a majority of fault was allocated away from J&J. Alameda County in particular has a long history of talc trials against J&J. The table sets Reikes against reported California talc verdicts and rulings. Figures are as reported; several have been reduced or are on appeal.

Case / forum	Date	Outcome	Reported detail
Echeverria (Los Angeles County)	August 2017	$417 million verdict (ovarian)	$70 million compensatory, $347 million punitive; trial judge later set the verdict aside and ordered a new trial
Leavitt (Alameda County)	March 2019	About $29.4 million verdict (mesothelioma)	$24.4 million to plaintiff, $5 million to her husband; no punitive damages
Hernandez Valadez (Alameda County), No. 22CV012759	July 2023	$18.8 million verdict (mesothelioma)	Tried during J&J's second bankruptcy after the stay was lifted for the plaintiff; J&J said it would appeal
Moore (Los Angeles County)	October 2025	$966 million verdict (mesothelioma)	$950 million punitive struck March 13, 2026; $16 million compensatory left in place
Kent and Schultz (Los Angeles County bellwether)	December 2025	$40 million verdict (ovarian)	$18 million and $22 million; first of six bellwethers before Judge Theresa Traber
Lozano (Los Angeles County, JCCP 4674)	June 9, 2026	$32 million verdict (mesothelioma)	$28 million past pain and suffering, $4 million to family; 100% fault to J&J; directed verdict for J&J on punitive damages
Reikes (Alameda County), No. 25CV157993	November 9, 2026	$34.21 million verdict (mesothelioma)	40% fault to J&J, 60% to Dr. Scholl's; no punitive damages

Three patterns stand out. First, California mesothelioma verdicts against J&J have clustered between about $18 million and $35 million in compensatory damages when punitive damages are out of the case: Hernandez Valadez, Leavitt, Lozano and Reikes all fall in that band, and the Moore compensatory award, at $16 million, sits just below it. That band is the practical benchmark for valuing a California mesothelioma claim against J&J. Second, punitive damages have not survived in recent California mesothelioma trials against J&J, whether through directed verdict (Lozano), post-trial ruling (Moore) or the jury's own verdict (Reikes). Third, Reikes is the first of these in which the alternative-exposure defense meaningfully reduced J&J's share, which makes the allocation the most consequential finding of the trial.

How does Reikes compare with J&J's national mesothelioma record this fall?

The J&J $34 million talc verdict in Reikes is the third talc mesothelioma verdict against J&J in less than three weeks, and the results have ranged from a defense win to eight figures:

• Ohio, October 23, 2026: an Ohio state jury returned a defense verdict for J&J in a wrongful death case brought by the family of a woman who alleged her mesothelioma was caused by asbestos-contaminated talc.
• Massachusetts, November 6, 2026: a Suffolk County Superior Court jury in Boston found J&J's baby powder caused former nurse Winifred Haddad's mesothelioma but not her 2020 death, awarding about $1.9 million. The plaintiffs' firm, Dean Omar Branham Shirley, said on November 10 that about $1.4 million in prejudgment interest brings the total award to just over $3,325,000, reflecting the state's 12% statutory interest rate.
• California, November 9, 2026: the Reikes jury awarded $34.21 million with a 40% fault share to J&J.

The spread illustrates how much state law, rather than the product evidence alone, drives outcomes. Massachusetts confines punitive damages to death cases and adds 12% interest from filing; California applies Proposition 51 and post-judgment interest at 10%; Ohio caps punitive damages and applies its own asbestos causation statute. A plaintiffs' firm valuing a mesothelioma docket against J&J must price each forum separately.

Does the J&J $5.5 billion talc settlement cover mesothelioma cases?

No. J&J's proposed resolution of the remaining talc litigation, announced July 27, 2026, is limited to ovarian cancer and other gynecological claims. Mesothelioma claims were never part of it. The company has said it has already resolved the large majority of filed mesothelioma lawsuits through separate settlements, and the remainder continue to be tried individually in state courts, which is why verdicts like Reikes and Haddad keep arriving while the ovarian deal is being assembled.

The ovarian deal, generally reported at $5.5 billion and taken as a third-quarter litigation charge of about $5.5 billion, is conditioned on at least 95% participation among the remaining claimants. Lead plaintiffs' counsel told the court in In re Johnson & Johnson Talcum Powder Products (MDL No. 2738, D.N.J.) in October 2026 that about 87.5% had signed. The multidistrict litigation had 69,376 pending actions as of the Judicial Panel on Multidistrict Litigation's November 2 report. Kenvue, J&J's former consumer health business, does not bear the cost: J&J retained talc liabilities in the United States and Canada and agreed to indemnify Kenvue for them.

The separate tracks matter for valuing the J&J $34 million talc verdict. A mesothelioma verdict is not direct evidence about the ovarian cases, whose general causation evidence and settlement matrix are different. It is evidence for the mesothelioma settlement market, where single-plaintiff verdicts set the price of the next tranche of claims. The path J&J took to reach this point is relevant too: its three attempts to resolve talc claims through bankruptcy, including the Texas Two-Step structure used for LTL Management and the later Red River Talc filing, were all dismissed, leaving case-by-case trials and a non-bankruptcy ovarian deal as the remaining tools.

California talc mesothelioma litigation: the legal framework

Several features of California law shape outcomes in cases like Reikes.

Liability theories. California recognizes strict products liability for manufacturing defect, design defect and failure to warn, alongside negligence. A talc plaintiff typically pleads both. The Reikes jury's two highlighted findings, that the product was defective and that the failure to warn was a substantial factor, track the strict-liability and warnings theories. In a talc case, a design defect theory usually rests on the contention that a product containing asbestos fibers fails the consumer-expectations test, while the failure-to-warn theory depends on what J&J knew or could have known about contamination risk.

Causation. Asbestos cases in California apply the substantial-factor standard from Rutherford v. Owens-Illinois (1997): a plaintiff must prove exposure to the defendant's asbestos-containing product and that, to a reasonable medical probability, the exposure was a substantial factor in contributing to the risk of developing cancer. That standard does not require the plaintiff to identify which fibers caused the disease. The fight in most talc trials, including Reikes, is over specific causation and product identification: whether the baby powder the plaintiff used actually contained asbestos, which turns on competing mineralogical testing evidence and on the admissibility of expert opinions under California's Sargon standard, the state's counterpart to a Daubert challenge.

Apportionment. Proposition 51 makes non-economic damages several in proportion to fault, and Arena extends that to separate products in strict liability cases. Juries therefore hear evidence about every product the plaintiff used, and a defendant can reduce its exposure without defeating liability.

Consortium. Tina Reikes' claim for loss of consortium rests on Rodriguez v. Bethlehem Steel Corp. (1974), in which the California Supreme Court recognized a spouse's cause of action for loss of consortium caused by negligent or intentional injury to the other spouse. Consortium damages are non-economic and therefore subject to the same proportional rule.

Damages caps. California has no cap on non-economic damages in product liability cases; the MICRA cap applies only to medical negligence. Juries therefore have wide latitude on pain and suffering, which is why the compensatory band for mesothelioma verdicts sits well into eight figures.

Trial preference. Code of Civil Procedure section 36 lets a party whose health raises substantial doubt about surviving beyond six months seek trial within 120 days. Mesothelioma plaintiffs regularly invoke it, which explains how a case filed in 2025 can reach verdict in late 2026 and why J&J faces a steady flow of California trials regardless of the pace of the MDL.

What the J&J $34 million talc verdict means for practitioners

For mesothelioma plaintiffs' firms. Reikes confirms that California juries continue to find J&J liable in talc mesothelioma cases, and that compensatory awards in the $18 million to $35 million range are achievable without punitive damages. It also shows the cost of a multi-product exposure history. Where a client used other talc products, the alternative-exposure defense is now a proven tool for shifting most of the non-economic damages away from J&J. Case selection, product identification for each powder, and settlement timing with other manufacturers before trial all affect what the client nets. A firm that settles with a co-defendant early should model how much of that settlement will be allocated to economic damages and credited to J&J.

For J&J and other talc defendants. The 40% allocation is a meaningful defense outcome in a losing trial. It suggests that developing evidence of exposure to other manufacturers' products, rather than relying solely on the argument that J&J's talc was asbestos-free, can cut exposure by more than half under Proposition 51. The absence of punitive damages in the last three California mesothelioma verdicts against J&J reduces tail risk, though the compensatory figures remain large.

For co-defendants and settling manufacturers. A 60% fault finding against a settled defendant has no direct effect on that defendant, whose settlement is final. It does inform future negotiations: other plaintiffs who used the same foot powder will cite the Reikes allocation as evidence of the product's contribution, and defendants in the same position may face higher settlement demands.

For insurers and funders. For carriers watching the J&J $34 million talc verdict from talc-related coverage positions and for funders financing mesothelioma dockets, Reikes is a data point in a widening distribution. The headline number is less important than the net judgment after allocation and credits, plus 10% post-judgment interest during an appeal. Funders underwriting contingency fee portfolios against J&J should model state-by-state outcomes, since the same product evidence produced a defense verdict in Ohio, a disease-but-not-death verdict in Massachusetts and an eight-figure allocated award in California within three weeks.

For courts managing talc dockets. The Reikes verdict, like Lozano, will feed arguments in coordinated California asbestos proceedings about how evidence of other products is presented, how verdict forms frame allocation questions, and how settlement credits are calculated when a settling defendant's share is assigned by the jury.

FAQ

How much did the jury award in the Reikes v. Johnson & Johnson talc case?

$34.21 million. An Alameda County Superior Court jury returned the verdict on November 9, 2026, in favor of Kevin Reikes, who has mesothelioma, and his wife Tina, in Reikes et al. v. Block Drug Company et al., No. 25CV157993.

Why was J&J found only 40% at fault?

The jury assigned the other 60% of fault to Dr. Scholl's foot powder, a second talc product Reikes used. Its maker settled before trial, but California's Proposition 51 lets juries allocate fault to settled defendants, and J&J's share of non-economic damages is limited to its 40%.

How much will J&J have to pay on the $34 million verdict?

The exact figure is not yet known. If the entire award were non-economic damages, J&J's 40% share would be about $13.68 million; any economic damages are owed in full, less a credit for the Dr. Scholl's settlement. Post-judgment interest at 10% per year then applies.

Did the Reikes jury award punitive damages against J&J?

No. The verdict is compensatory only. California requires clear and convincing evidence of malice, oppression or fraud for punitive damages, and recent California talc mesothelioma trials against J&J have not produced a surviving punitive award.

Is the Reikes case part of J&J's $5.5 billion talc settlement?

No. J&J's proposed $5.5 billion resolution covers ovarian cancer and gynecological claims only. Mesothelioma cases, including Reikes and the Massachusetts Haddad case, are litigated or settled separately in state courts.

Will J&J appeal the Alameda County talc verdict?

An appeal is expected. J&J has said it would appeal its recent adverse mesothelioma verdicts, including Lozano in June 2026 and Haddad in November 2026. Post-trial motions come first, then a notice of appeal to the First District Court of Appeal within the deadlines set by the California Rules of Court.